Annual Colloquium on Precision Oncology & Next-Gen Therapeutics
A peer-reviewed academic gathering convening clinical oncologists, laboratory geneticists, and translational research teams. The two-day program evaluates clinical trial findings, molecular alterations, synthetic cellular constructs, and clinical biomarker assay validation in solid and hematologic malignancies.
Scientific Program Scope & Practice Framework
Translating high-throughput molecular discoveries into verified frontline oncology interventions.
Precision oncology relies heavily on resolving high-throughput genomic and transcriptomic sequencing into actionable therapeutic regimens. While single-cell platforms have broadened the landscape of targetable mutations, establishing durable patient responses remains constrained by clonal evolution, targeted resistance mechanisms, and the immunosuppressive microenvironment of solid tumors.
The Annual Colloquium on Precision Oncology & Next-Gen Therapeutics (PrecisionOnco 2027) provides an academic forum for laboratory investigators, translational scientists, and hospital clinicians. Over two days of didactic plenaries, proffered oral presentations, and moderated poster discussions, participants examine preclinical target validation, phase I–III clinical trials data, and synthetic receptor engineering.
Curriculum priorities include analytical thresholds in minimal residual disease (MRD) monitoring, cell-free DNA (cfDNA) assays, and rational co-inhibition strategies designed to anticipate secondary resistance mutations.
Academic Governance
- Double-blind scientific abstract evaluation by an independent academic program committee.
- Strict firewall separating scientific sessions from commercial sponsorship influence.
- Adherence to Declaration of Helsinki standards and local IRB trial compliance.
- Dedicated question-and-answer floor periods built into each plenary session.
Scientific Tracks & Subject Taxonomy
Proffered abstracts and podium sessions are categorized across four primary disciplines.
Multi-Omics Profiling & Neoantigen Identification
- Whole-genome, exome, and spatial transcriptomics in treatment-refractory tumors.
- Computational prediction of patient-specific neoantigen-HLA presentation.
- Epigenetic drivers of immune evasion and therapeutic resistance.
- Integration of single-cell sequencing into initial therapeutic decision trees.
Cellular & Gene-Directed Immunotherapies
- Multi-antigen targeting CAR-T constructs and synthetic notch receptor systems.
- Allogeneic and non-viral cell modification platforms for solid tumor targets.
- Overcoming dense stroma and immunosuppressive barriers in solid tumor beds.
- Cellular engineering protocols to reduce systemic inflammatory toxicities.
Liquid Biopsy, ctDNA & Minimal Residual Disease
- Circulating tumor DNA methylation markers for early relapse detection.
- Multiplexed extracellular vesicle and CTC characterization across treatment courses.
- Analytical thresholds, assay reproducibility, and standard reference materials.
- Integrating MRD readouts into clinical trial endpoints and adaptive protocols.
Mechanisms of Resistance & Combination Regimens
- Structural characterization of on-target and bypass alterations (KRAS, EGFR, MET).
- Antibody-Drug Conjugates (ADCs): Linker optimization, payload toxicity, and resistance.
- Mechanistic sequencing of targeted small molecules paired with checkpoint inhibitors.
- Overcoming metabolic immunosuppression in hypoxic solid tumor microenvironments.
Target Audience & Educational Objectives
Structured to align basic biological discovery with hospital clinical oncology practice.
Intended Target Audience
This educational activity is organized for oncology researchers, pathologists, and clinicians:
- Medical, Surgical & Hematologic Oncologists: Evaluating prospective clinical trial data, targeted treatment sequencing, and therapy selection for refractory cases.
- Cancer Biologists & Laboratory Geneticists: Investigating neoantigen biology, synthetic cell engineering, oncogenic signaling, and chromatin mechanics.
- Clinical Pathologists & Molecular Diagnostic Specialists: Standardizing next-generation sequencing assays, liquid biopsy protocols, and immunohistochemical profiling.
- Clinical Fellows, Postdoctoral Trainees & Residents: Presenting original investigations and reviewing translational methods with senior investigators.
- Biopharma & Translational R&D Investigators: Developing targeted biologicals, antibody payloads, small-molecule inhibitors, and non-viral delivery modalities.
Educational Learning Objectives
Upon completion of the 14.5 contact-hour curriculum, participants will be equipped to:
- Differentiate Actionable Genomic Variants: Correlate complex next-generation sequencing outputs with validated targeted therapies in solid tumors.
- Assess Cell Therapy Protocols: Evaluate mechanistic designs and safety protocols for engineered CAR-T constructs and synthetic T-cell engagers.
- Apply ctDNA & Liquid Biopsy Assays: Assess limit-of-detection standards and clinical validity when using circulating markers for minimal residual disease detection.
- Address Secondary Resistance Mutations: Formulate rational dual-inhibitor combinations or ADC regimens to bypass predictable downstream signaling reactivations.
Important Deadlines & Schedule
The academic committee evaluates abstract submissions and delegate registrations on a rolling timetable. Please observe the formal dates below.
Colloquium Participation Tiers
All in-person passes include credentialed access to all scientific tracks, colleague luncheons, conference dossiers, and verification for 14.5 Educational Contact Hours.
Clinical Delegate & Faculty (Non-Presenting Observer Pass)
For physicians, laboratory heads, and research investigators attending to audit plenaries, join interactive discussions, and claim 14.5 contact hours without submitting an abstract.
Accepted Presenting Author (Oral Talk or Poster Defense)
Subsidized author registration. Includes assigned podium time or poster board allocation, official abstract publication in the program compendium, and full delegate credentials.
Student / Fellow / Resident (Institutional Verification Required)
Subsidized institutional rate for medical oncology fellows, residents, and graduate students. Verification letter from department chair or lab director required upon badge check-in.
Looking for Workshop-Only passes, Listener access, or Remote E-Poster tracks?
View Complete Registration Fee Schedule & Institutional Invoice Details →Diagnostics Showcase, NGS Platforms & Venture Matchmaking
Bridging laboratory assay developers, instrumentation providers, and life-science investors with clinical oncology department chairs who evaluate and procure diagnostic assays.
Diagnostic & NGS Tabletop Showcase
Turnkey 6ft tabletop display positioned directly in the central coffee concourse and poster viewing corridor. High-density facetime with core facility directors.
Biomarker & Diagnostic Partnering Pass
Designed for seed/Series-A venture investors and pharma search scouts. Includes entry to the 1-on-1 partnering lounge and unencumbered pre-clinical patent directory.
Precision Diagnostic Plenary Sponsor
Prime 3x3m concourse booth alongside a 15-minute plenary luncheon technology case study presentation highlighting clinical assay sensitivity/specificity.
Reverse VC & Licensing Stage Partner
A 45-minute main-stage address presenting your fund thesis and deployment criteria to presenting laboratory heads seeking translation funding and corporate spinout backing.